TY - JOUR
AB - PharmacoEconomics & Outcomes News 747, p1 - 27 Feb 2016 GSK fined £38 million for delaying generic paroxetine One of the biggest drug makers, GlaxoSmithKline (GSK) has been fined more than £37.6 million ($US55 million) for anticompetitive behaviour by striking deals between 2001 and 2004 to delay the release of a generic version of its antidepressant, paroxetine. GSK received the fine from the UK’s Competition and Markets Authority (CMA) for its "pay for delay" deals – totalling around £50 million in cash – with generic manufacturers to delay generic paroxetine from entering the UK market. With sales exceeding £90 million, the CMA concluded that the deals "potentially deprived the NHS of the significant price falls that generally result from generic competition . . . In this case, when independent generic entry eventually took place at the end of 2003, average paroxetine prices dropped by over 70% in two years". The investigation began in 2010 when the European Commission brought the agreements to the attention of the now disestablished Office of Fair Trading, and in the US, similar deals have been investigated, with the Supreme Court ruling that such agreements could be challenged under antitrust laws. GSK has indicated it 
TI - GSK fined £38million for delaying generic paroxetine
JF - PharmacoEconomics & Outcomes News
DO - 10.1007/s40274-016-2815-9
DA - 2016-02-27
UR - https://www.deepdyve.com/lp/springer-journals/gsk-fined-38million-for-delaying-generic-paroxetine-fzLlxM9bV1
SP - 1
EP - 1
VL - 747
IS - 1
DP - DeepDyve
ER -